Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

MLA

Moore, Kathleen N., et al. “Niraparib Monotherapy for Late-Line Treatment of Ovarian Cancer (QUADRA): A Multicentre, Open-Label, Single-Arm, Phase 2 Trial.” The Lancet. Oncology, vol. 20, no. 5, May 2019, pp. 636–48. EBSCOhost, https://doi.org/10.1016/S1470-2045(19)30029-4.

APA

Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N., Fleming, G. F., Wahner Hendrickson, A. E., Azodi, M., DiSilvestro, P., Oza, A. M., Cristea, M., Berek, J. S., Chan, J. K., Rimel, B. J., Matei, D. E., Li, Y., Sun, K., Luptakova, K., Matulonis, U. A., & Monk, B. J. (2019). Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. The Lancet. Oncology, 20(5), 636–648. https://doi.org/10.1016/S1470-2045(19)30029-4

Chicago

Moore, Kathleen N, Angeles Alvarez Secord, Melissa A Geller, David Scott Miller, Noelle Cloven, Gini F Fleming, Andrea E Wahner Hendrickson, et al. 2019. “Niraparib Monotherapy for Late-Line Treatment of Ovarian Cancer (QUADRA): A Multicentre, Open-Label, Single-Arm, Phase 2 Trial.” The Lancet. Oncology 20 (5): 636–48. doi:10.1016/S1470-2045(19)30029-4.